
-
Affimed N.V. NasdaqGM:AFMD Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Location: Gottlieb-Daimler-Straße 2, Mannheim, 68165, Germany | Website: https://www.affimed.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-9.654M
Cash
24.1M
Avg Qtr Burn
-19.23M
Short % of Float
3.75%
Insider Ownership
6.01%
Institutional Own.
19.89%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AFM13 (Acimtamig) + AB-101 Details Cancer, Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphomas | Phase 2 Data readout | |
AFM24 (tumor target EGFR) w/ SNK01 & atezolizumab Details Non-small cell lung carcinoma | Phase 2 Update | |
AFM13 (Acimtamig)+ cbNK cells Details Cancer, Non-Hodgkin lymphoma | Phase 2 Update | |
AFM13 (Acimtamig) Details Peripheral T cell cancer , Cancer | Phase 2 Initiation | |
AFM28 Details Cancer, Blood cancer, Leukemia, Acute myeloid leukemia | Phase 1 Data readout | |
AFM24 (tumor target EGFR) Monotherapy Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Colorectal cancer | Failed Discontinued | |
RO7297089 (formerly AFM26) Details Multiple myeloma, Cancer | Failed Discontinued |